OncoMatch/Clinical Trials/NCT04378647
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
Is NCT04378647 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Induction with Brentuximab vedotin (BV) and Induction without Brentuximab Vedotin for hodgkin lymphoma, adult.
Treatment: Induction with Brentuximab vedotin (BV) · Induction without Brentuximab Vedotin · Consolidation with Brentuximab Vedotin — A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Hodgkin Lymphoma
Biomarker criteria
Required: CD30 positive (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: brentuximab vedotin (brentuximab vedotin)
Prior treatment with brentuximab vedotin
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04378647 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior brentuximab vedotin disqualifies patients from enrollment.
Does this trial require CD30?
Yes, CD30 positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages